Sarah B. Noonberg
Sarah B. Noonberg is on the board of Protagonist Therapeutics, Inc. and Neoleukin Therapeutics, Inc. She previously occupied the position of Chief Medical Officer at Prothena Corp. Plc, Chief Medical Officer of Nohla Therapeutics, Inc., Group VP & Head-Global Clinical Development at BioMarin Pharmaceutical, Inc., Director-Clinical Development at Chiron Corp. and SVP-Early Development & VP-Clinical Development at Medivation LLC (California).
She received a doctorate from The University of California, San Francisco, a doctorate from the University of California, Berkeley and an undergraduate degree from Dartmouth College.
Transactions
Date
Transaction
Value
| 02/11/2021 | 3,700 | Disposition at $25.09 per share. | 92,833 |
| 02/11/2021 | 3,700 | Award at $6.98 per share. | 25,826 |
| 02/10/2021 | 400 | Disposition at $26.04 per share. | 10,416 |
| 02/10/2021 | 4,300 | Disposition at $25.42 per share. | 109,306 |
| 02/10/2021 | 4,700 | Award at $6.98 per share. | 32,806 |
